Redx Pharma (LSE:REDX) Pre-Tax Income : £-32.79 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Redx Pharma's pretax income for the six months ended in Sep. 2023 was £-12.14 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was £-32.79 Mil. Redx Pharma's pretax margin was -642.04%.

During the past 12 years, Redx Pharma's highest Pretax Margin was 5.40%. The lowest was -7865.12%. And the median was -202.33%.

Redx Pharma Pre-Tax Income Historical Data

The historical data trend for Redx Pharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Pre-Tax Income Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Pre-Tax Income

Get a 7-Day Free Trial

-6.34

-9.17

-21.44

-17.80

-32.79

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Pre-Tax Income	Get a 7-Day Free Trial															-8.78	-9.68	-8.12	-20.65	-12.14

Competitive Comparison of Redx Pharma's Pre-Tax Income

For the Biotechnology subindustry, Redx Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redx Pharma's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Redx Pharma's Pre-Tax Income falls into.

Redx Pharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Redx Pharma's Pretax Income for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-30.98	+	0	+	-1.801	+	1.224	+	-1.231
	=	-32.79

Redx Pharma's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-13.362	+	0	+	-0.904	+	0.52	+	1.605
	=	-12.14

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-32.79 Mil.

Redx Pharma (LSE:REDX) Pre-Tax Income Explanation

Redx Pharma's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-12.141	/	1.891
	=	-642.04%

During the past 12 years, Redx Pharma's highest Pretax Margin was 5.40%. The lowest was -7865.12%. And the median was -202.33%.

Redx Pharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines